Navigation Links
Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
Date:10/30/2007

EMERYVILLE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), a specialty biopharmaceutical company, today announced the pricing of an underwritten offering of its common stock to raise $60 million in gross proceeds at a public offering price of $2.75 per share. All of the shares in the offering are being sold by the Company. The offering is expected to close on November 2, 2007 and the Company will receive approximately $55 million of net offering proceeds, after underwriting discounts and estimated costs.

Merriman Curhan Ford & Co. (Amex: MEM) acted as the sole book-running manager in this offering, and Dawson James Securities, Inc. acted as co-manager.

Copies of the final prospectus may be obtained from:

Merriman Curhan Ford & Co.

600 California Street, 9th Floor

San Francisco, CA 94108

via phone: (415) 248-5600

via fax: (415) 248-5690

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous syst
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , The New York investmen... Ltd (ASX:NEU) has agreed an AU$6.7 mil convertibl... investor. The private placement was arranged by K...nd advisor. , New York (P...k investment bank KTA Capital, LLC ("KTA Capi...
(Date:11/24/2009)... , , ST. LOUIS, Nov. 24 /PRNewswire-Fi...AL ) will be presenting at the NASDAQ OMX conferen...on, 7:45 AM US/CST. Interested parties may listen ...le at http://inve s tor.sig m a a ldrich.c...ss this file. ,, About Sigma-Aldrich: Sig...
(Date:11/24/2009)... , , SAN MATEO, Calif., Nov. 24 /PRNe...X ), a biopharmaceutical company focused on develo...rapies, announced today that Anthony DiTonno, Pres... present at the 21st Annual Piper Jaffray Health C...he New York Palace Hotel in New York, New York. ,...
(Date:11/24/2009)... , , , Primary efficacy endpoint has ...ecurrent endometrial cancer, , QUEBEC CITY, N...nc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a ...ine therapy and oncology, today announced positive...ted cytotoxic peptide conjugate, AEZS-108 (formerl...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...K, May 7 /PRNewswire-FirstCall/ -- Delcath Syst...gy company testing its proprietary Percutaneous He... of cancers of the liver, announced today that Eri...a Center and a Principal Investigator of Delcath,s...ngress on Melanoma, to be held in Vienna, Austria,...
...MA, Italy, May 7 The Parma Group has reacquired t...s laying the groundwork to,acquire control of the ...ll,be setting up its twenty-third associated compa...This presence in the USA will prepare the way for,...espiratory illnesses. , The Chiesi Group has c...
... Calif., May 7 BioMarin Pharmaceutical Inc. (Nasd...ce President of Business and Corporate Development... Baird Growth Stock Conference in Chicago on Thurs...ted parties may access a live audio webcast of the...ioMarin website, www.BMRN.com . A replay of th...
Other Biology Technology:Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma 2Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma 3The Chiesi Group Lands in the United States 2The Chiesi Group Lands in the United States 3BioMarin to Present at the Baird Growth Stock Conference 2
(Date:11/26/2009)...hicillin-resistant Staphylococcus Aureus ) and ot...n as low-temperature plasma prototype devices have...ailing bactericidal cocktails. , Two prototype d...nfection of healthy skin (e.g. hands and feet) in ...e a lethal threat; and another to shoot bacteria-k...
(Date:11/25/2009)...ber 11, firefighters, police officers and ambulanc...World Trade Center complex. They battled to save p...r survivors, tackled fires and evacuated as many p...estimated 17,000 people. And making their jobs eve...rightened workers and their relatives jammed mobil...
(Date:11/25/2009)...State University assistant professors recently rec... (NSF) to continue research beneficial to understa...,000. , Christopher Blackwood, assistant profess...warded grants to support two separate research pro...itter Decomposer Communities and Functions from th...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Kent State University professors focus research on the environment with grants totaling $890,000 2Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 1Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 2Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 3Parents In Kansas Can Now Test Their Children For Lead Exposure Using Saliva 47727 4Oxygen + MRI might help determine cancer therapy success researchers find 47725 1Oxygen + MRI might help determine cancer therapy success researchers find 47725 2Dr Erika says Newsweeks Attack on Oprah Ignores the Many Benefits of Her Health Care Advocacy 47723 1Dr Erika says Newsweeks Attack on Oprah Ignores the Many Benefits of Her Health Care Advocacy 47723 2
...any researchers have believed women choose partner...ng, a new study from The University of Texas at Au...by their own attractiveness. , David Buss, psycho...he findings in Attractive Women Want it All: Good ... and Emotional Commitment in this months Evolution...
... neuron disease is a rare, devastating illness in ...les gradually deteriorate. One form of it, Lou Geh...), is familiar to the public in the lives of scien...om Mitch Alboms Tuesdays with Morrie was written. ...iguring out why these people develop the disease, ...
... Purdue University researchers have identified sev...the Midwest like southern Indiana and are resistan...ite with a recently confirmed presence in that par...esistance in soybeans to one nematode parasite doe...ther nematode species, said Andreas Westphal, assi...
Other Biology News:Do attractive women want it all? 2Motor neuron disease and toxic substances: Possible link? 2Motor neuron disease and toxic substances: Possible link? 3Soybean varieties viable in southern Indiana, resistant to root-knot nematode 2Soybean varieties viable in southern Indiana, resistant to root-knot nematode 3
Mouse Anti-Human KAI 1 Monoclonal Antibody, Unconjugated, Clone G-2 from Santa Cruz Biotechnology, Inc.
Rat Anti-Mouse TCR, Va 2 Monoclonal Antibody, Unconjugated, Clone B20.1 from CEDARLANE Laboratories Limited
Rat Anti-Mouse OSMR Monoclonal Antibody, Unconjugated, Clone 30-1 from MBL International
...gned for use with the ProQuest Two-Hybrid System (...letions in the endogenous GAL4 and GAL80 genes for...n also has leu2 and trp1 mutations for selection o...three GAL4 inducible reporter genes, providing fou...
Biology Products: